James C-Y Chou
- ASSOCIATE CLINICAL PROFESSOR Psychiatry
Dr. Chou's research interests include psychopharmacology of bipolar disorder and schizophrenia as well as the neurobiological underpinnings of psychopharmacologic treatments. He has extensive experience in clinical trials for bipolar disorder, schizophrenia, and depression. He is studying the brain pathways of emotional processing in bipolar disorder using functional magnetic resonance imaging. Additional interests include cross-ethnic psychopharmacology, clinical trials, and continuing education of psychiatrists
Keywords: Bipolar disorder, schizophrenia, antipsychotic, anticonvulsant, lithium, brain imaging, fMRI, education, depression, mood stabilizer, CME
Chou JY. Clinical applications of antipsychotic pharmacodynamics and pharmacokinetics. In: Advances in Psychiatric Medicine (Targeting Novel Therapies in Schizophrenia: Considerations for Physicians and Patients), Psychiatric Times (supplement). pp1-2.
Chou JY, Fazzio L. Maintenance Treatment of Bipolar Disorder -Applying Research to Clinical Practice. J Psych Practice 2006; 12: 281-299.
Chou JY. Review and Update of the APA Practice Guideline for Bipolar Disorder. Primary Psychiatry 2004; 11(9): 73-84.
Currier GW, Chou JY, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, Gharabawi G. Acute treatment of psychotic agitation: A randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. Journal of Clinical Psychiatry 2004; 65: 386-394.
Chou JY, Czobor P, Dacpano G, Richardson N, Tuma I, Trujillo M, Cooper TB, Volavka J. Haloperidol blood levels in Acute Mania. J Clinical Psychopharmacology 2001; 21: 445-447.
Chou JY, Solhkhah R, Serper M. Clinical Research on Antipsychotics in Bipolar Disorder. J Psychiatric Practice 2000 November;: 310-321.
Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr., Chou JY, Keck PE Jr., Rhodes LJ, Swann AC, Hirschfeld RA, Wozniak for the Divalproex Maintenance Study Group PJ. A Randomized, Placebo-Controlled 12-Month Trial of Divalproex and Lithium in Treatment of Outpatients With Bipolar I Disorder. Arch Gen Psychiatry 2000; 57: 481-489.
Chou JY, Czobor P, Tuma I, Charles O, Bebe R, Cooper TB, Chang WH, Lane HY, Stone D. Pretreatment plasma HVA and haloperidol response in acute mania. J Affective Disorders 2000; 59: 55-59.
Chou JY, Czobor P, Charles O, Tuma I, Wisberg B, Allen MH, Trujillo M, Volavka J. Acute Mania: haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychopharmacology 1999; 19(6): 500-505.
Chou JC, Douyon R, Czobor P, Volavka J, Cooper TB. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research 1998; 81: 51-55.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Chou is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.